Phathom Pharmaceuticals (PHAT) Revenue (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Revenue data on file, last reported at $58.3 million in Q1 2026.

• On a quarterly basis, Revenue rose 104.43% year-over-year to $58.3 million in Q1 2026; TTM through Mar 2026 was $204.9 million, a 150.3% increase from a year earlier, with the FY2025 full-year figure at $175.1 million, up 216.93% from the prior year.
• Revenue for Q1 2026 stood at $58.3 million, up from $57.6 million in the prior quarter.
• Over the last five years, Revenue for PHAT reached as high as $58.3 million in Q1 2026 and fell as low as $682000.0 in Q4 2023.
• Historically, Revenue has averaged $28.9 million across 4 years, with a median of $29.1 million in 2024.
• Across the five-year window, Revenue surged 4249.56% in 2024 and jumped 94.12% in 2025, its largest moves.
• Year by year, Revenue stood at $682000.0 in 2023, then jumped by 4249.56% to $29.7 million in 2024, then surged by 94.12% to $57.6 million in 2025, then gained by 1.25% to $58.3 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $58.3 million in Q1 2026, $57.6 million in Q4 2025, and $49.5 million in Q3 2025.